Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Liabilities and Shareholders Equity (2016 - 2025)

Cytosorbents (CTSO) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $45.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 4.3% year-over-year to $45.8 million, compared with a TTM value of $141.1 million through Sep 2025, down 29.99%, and an annual FY2024 reading of $47.4 million, down 11.06% over the prior year.
  • Liabilities and Shareholders Equity was $45.8 million for Q3 2025 at Cytosorbents, down from $48.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $98.2 million in Q2 2021 and bottomed at $45.8 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $63.9 million, with a median of $55.4 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity surged 99.34% in 2021, then tumbled 34.5% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $89.5 million in 2021, then dropped by 29.37% to $63.2 million in 2022, then decreased by 15.77% to $53.3 million in 2023, then dropped by 11.06% to $47.4 million in 2024, then fell by 3.42% to $45.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CTSO at $45.8 million in Q3 2025, $48.0 million in Q2 2025, and $47.4 million in Q4 2024.